IDEX IEX
Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-07-03
The Overview
IDEX makes highly specialized pumps, flow meters, and precision fluid parts — the unglamorous but essential bits inside water systems, lab instruments, fire trucks, and semiconductor and data-center equipment. It buys up small niche manufacturers, improves them, and collects steady profits: it keeps about 44 cents of gross profit on every sales dollar and about 14 cents of bottom-line profit. It is a well-run, boring, profitable machine.
The catch: the stock is not cheap. You're paying roughly 26 times next year's expected earnings for a company growing sales only about 3–4% a year on its own (more once you add acquisitions). That's a full price for modest growth, so the upside from here is limited unless management keeps buying good companies cheaply. Our verdict is Watch — a quality business worth owning, but wait for a better entry price.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly low). Low debt and an average-swinging stock make it sturdy — but the rich price and its dependence on the industrial economy mean a stumble would hurt.
- Growth Quality 6/10 (good). A profitable, well-run business that grows steadily — just not fast.
- Exponential Potential 3/10 (low). This is a mature compounder. Don't expect it to double quickly; expect slow, steady gains.
The one big worry: you're paying a premium for a company whose own sales barely grow; if the economy softens or its acquisition machine slows, the stock could fall back to a cheaper multiple.
Putting a number on it: our fair-value estimate is $232 against a current price of $230.28 — real upside if our numbers are right.
Our summary metrics
Low leverage (net-debt/EBITDA 1.4×) and beta ~1.0 — but 26× forward earnings for ~mid-single-digit growth and industrial cyclicality.
~10% forward EPS CAGR, 44% gross margin, ROIC ~9%, durable niche moat — solid, not spectacular.
Mature multi-industry compounder; ~6% revenue CAGR, decelerating from 2021-22 M&A surge, $16.6B cap with modest room to run.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Mature multi-industry compounder; ~6% revenue CAGR, decelerating from 2021-22 M&A surge, $16.6B cap with modest room to run.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $244.71 (high $257 / low $214; 14 Buy · 15 Hold · 0 Sell → Hold) — context, not our anchor |
| Valuation | 33× trailing GAAP EPS · 26× FY26E · 24× FY27E · 19× FY29E (adj. EPS) · EV/S 5.1× · EV/EBITDA 19× |
| Technicals | Uptrend — $224, −1.9% off 52-wk high, above 50/200-DMA, RSI 63, +24% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices in KB; call rests entirely on fundamentals + quant |
| Position sizing | Watch-list / small quality-industrial sleeve, ~1–2% only on a pullback |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for IEX — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $230.28, 1% above the 50-day average ($229), 13% above the 200-day average ($204) — an uptrend. 4% below the 52-week high of $241, 45% above the 52-week low of $159.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $230.28 is currently inside the band (band $229–$241).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 47.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 1.05, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = IEX · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
IDEX Corporation (NYSE: IEX) is a Northbrook, Illinois multi-industry manufacturer of engineered fluidics — pumps, flow meters, injectors, dispensing and precision fluid-handling components — assembled over decades through a disciplined niche-acquisition ("roll-up") strategy and run on an 80/20 operating model. Founded 1987, ~9,000 employees, CEO Eric D. Ashleman. Fiscal year ends December 31. It operates three reportable segments:
- Health & Science Technologies (HST) — precision fluidics, optics, sealing and pneumatic components for life sciences, analytical instruments, semiconductors and, increasingly, AI data-center power and space/defense. The growth engine.
- Fluid & Metering Technologies (FMT) — positive-displacement pumps, flow meters and injectors for water, chemical, energy and industrial end-markets. The steady cash core.
- Fire & Safety / Diversified Products (FSDP) — firefighting pumps, rescue tools, engineered banding/clamping, and paint/colorant dispensing. The most cyclical, project-timing-sensitive leg.
Revenue mix (FY2025, from filings):
- By segment: HST $1,495.5M (43%) · FMT $1,224.0M (35%) · FSDP $745.3M (22%). HST is now the largest and fastest-growing segment.
- By geography: United States $1,760.8M (~51%) · Europe $846.2M (24%) · Asia $563.0M (16%) · North America ex-US $129.7M. Roughly half US, half international — a balanced, cyclical, capital-goods revenue base.
The strategic story management is telling: reallocate capital (via 80/20) toward higher-growth, higher-margin platforms inside HST — notably fluidics riding AI-driven data-center power and semiconductor demand — while the FMT/FSDP base funds dividends, buybacks and bolt-on M&A.
2. The expert thesis
There is no expert coverage of IEX in the Synthos knowledge base. total_claims = 0, breadth 0, net conviction 0. None of the tracked high-signal voices we distill have made a traceable, dated claim on IDEX.
What this means for the verdict: this note is entirely fundamentals- and quant-driven. We do not manufacture conviction we do not have — there is no panel here to lean on, bullish or bearish. That absence is itself information: IDEX is a quiet, well-run industrial that does not attract the concentrated, high-conviction attention that megacap growth or AI names do. The call below rests on the reported financials, the analyst-estimate consensus (FMP), management's own guidance (§9, half-weighted), and Synthos's quant scoring — nothing is cited to a claim_id because none exists.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Net-debt/EBITDA 1.4×, current ratio 3.4×, beta ~0.99, shallow max drawdown (−9%) — financially sturdy. Offsets: 26× forward earnings for mid-single-digit organic growth, and genuine industrial cyclicality (FMT/FSDP). |
| Growth Quality | 6 · Good | ~10% forward adj-EPS CAGR, 44% gross / 27% EBITDA margin, ROIC ~9% and ROE ~13%, durable niche pricing power. Solid compounder — but organic growth is only ~3–4% and ROIC is good-not-elite. |
| Exponential Potential | 3 · Low | Mature roll-up; ~6% revenue CAGR, decelerating off the 2021–22 M&A-fueled surge. $16.6B cap in a fragmented but not explosive TAM. AI/semis fluidics is a real tailwind but a minority of revenue. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | HST AI/semis/defense demand compounds; a value-accretive acquisition or two lands; organic growth re-accelerates to mid-single digits. FY27E adj-EPS beats to ~$9.75 (vs $9.23 cons); multiple holds a premium ~29×. | ~$285 (+27%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj-EPS ~$9.23; a durable mid-single-digit-organic compounder earns a ~25× multiple. | ~$232 (+4%) |
| Bear | Industrial cycle rolls over; HST life-sciences softness persists; M&A engine stalls or overpays. FY27E adj-EPS misses to ~$8.30; multiple de-rates to a cyclical ~21×. | ~$175 (−22%) |
Synthos fair value = the base case, ~$232 (+4%), with the full $175–$285 span as the honest range. Our base sits below the Street's $244.71 consensus — we are less willing to pay up for mid-single-digit organic growth. This is a tracked call; the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). IEX is a quality compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY29E ~6.0% ($3.44B → $4.34B est); adjusted-EPS CAGR ~9.9% ($7.89 → $11.52 est) as margins and buybacks help. Steady, not explosive.
- Acceleration (the 2nd derivative) is negative: revenue jumped +15.1% (FY21) and +15.1% (FY22) on the big AMETEK-era and Muon/Nexsight-style acquisition wave, then decelerated to roughly flat FY23–24 and +5.8% FY25. Organic growth is guided to just 3–4% for FY26 (management, §9). The M&A surge already happened; from here IEX grows in the mid-single digits. Per our flagship philosophy we favor forward accelerating names — IEX is the opposite: a decelerating mature compounder.
- Room to run: the niche-fluidics TAM is fragmented (which fuels the bolt-on strategy) but not a hyper-growth category. At $16.6B cap, a 3× from here (~$50B) is conceivable only over a very long horizon via relentless M&A — not a near-term multibagger.
- Genuine bright spot: HST's exposure to AI data-center power, semiconductors, and space/defense is a real accelerant (segment organic +11% in Q1'26) — but it is under half of revenue and does not move the whole ship fast enough to change the exponential read.
Exponential Potential: Low (3/10). Own IEX for durable ~10% earnings compounding and dividend growth, not for a fast multibagger. Honest framing: this is a Watch-and-own-on-weakness quality name, not a Degen-tier grower.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $3.458B, +5.8% (FY24 $3.269B, −0.2% vs FY23 $3.274B). Growth stalled FY23–24 after the 2021–22 acquisition surge, re-accelerated modestly in FY25. Q1'26 $886.9M, +9% reported / +5% organic (management).
- Quarterly trajectory: Q1'25 $814.3M → Q2 $865.4M → Q3 $878.7M → Q4 $899.1M → Q1'26 $886.9M (+8.9% YoY). Orders a record $988M in Q1'26 (+13%), a constructive leading indicator.
- Margins: gross 44.4% TTM, EBITDA 26.6% TTM, operating ~20.8%, net 14.4% TTM. Consistent, high-quality margins for an industrial — a hallmark of the 80/20 model and pricing power.
- Earnings: FY25 GAAP net income $483.2M, GAAP EPS $6.41 (FY24 $6.67). Note: management reports on an adjusted basis — FY25 adjusted EPS was meaningfully higher, and the FMP analyst-estimate series ($7.89 FY25 → $11.52 FY29E) tracks that adjusted line. We use adjusted EPS for forward multiples and label it as such.
- Cash flow: operating CF $680.4M, capex −$63.6M (light, ~1.9% of sales), FCF $616.8M FY25 (FCF margin ~18%). High cash conversion is a real strength.
- Balance sheet: cash $580M, total debt $1.849B, net debt $1.269B, net-debt/EBITDA 1.40×, current ratio 3.4×, interest coverage ~11×. Investment-grade, plenty of capacity for bolt-on M&A. Goodwill + intangibles are $4.66B (67% of assets) — the flip side of a roll-up; tangible book is negative.
6. Valuation — priced in or room?
IEX is not cheap, not egregious. On trailing GAAP it is 33× EPS (5.1× sales, 19× EV/EBITDA). On the adjusted line management and analysts use, the forward P/E is ~26× (FY26E $8.50) → ~24× (FY27E $9.23) → ~19× (FY29E $11.52) — the multiple only compresses to reasonable if the ~10% adj-EPS CAGR actually lands. The FMP letter rating is B (overall 3/5), flagging P/E and P/B as the weak scores and ROE/ROA as the strong ones — a fair "quality-at-a-full-price" summary. A PEG of ~2.6× on TTM earnings underlines that you are paying up for quality, not growth.
Street targets (context): consensus $244.71, high $257, low $214, median $250 — i.e. the sell-side sees ~9% upside, but the rating is a Hold (14 Buy / 15 Hold / 0 Sell). Our ~$232 base fair value is modestly below consensus because we apply a more conservative ~25× exit multiple to mid-single-digit organic growth. Not a value buy; a quality-industrial-at-full-price that we'd rather own cheaper.
7. Technicals (from the tech block)
- Trend: up. $223.82 sits above the 50-DMA ($215.49) and 200-DMA ($191.57), and the 50 is above the 200 (golden-cross posture). MACD +3.48 (positive).
- Location: just −1.9% off the 52-week high ($228.07), +42% off the 52-week low ($157.53) — near highs, with a modest max drawdown of −9.0% over the window (low volatility, as befits beta ~0.99).
- Momentum: RSI(14) 63 — strong but not overbought (<70), so no stretched-entry warning, though little room before it gets there.
- Relative strength: IEX +24.2% 12-mo vs SPY +20.6% — a slight edge over the market, but lagging QQQ +30.3%. +16.6% 3-mo vs SPY +13.7%.
- Read: technicals are constructive and confirm a healthy uptrend, but the stock is near its highs with RSI in the low-60s — consistent with our fundamental call to wait for a pullback (e.g. toward the rising 50-DMA ~$215 or lower) rather than chase.
8. Moat & competitive position
IDEX's moat is niche dominance at small scale: hundreds of engineered products where IDEX holds #1/#2 share in tiny, mission-critical categories with high switching costs (a pump spec'd into an FDA-approved analytical instrument or a municipal water system is sticky for years). Layered on top: a disciplined 80/20 operating model and a proven serial-acquisition engine that buys fragmented niche manufacturers and lifts their margins. Durable, but not a wide-moat monopoly — it is a diversified portfolio of small moats, and organic growth ultimately tracks the industrial cycle.
Peer set (market cap): Nordson $16.2B, ITT $16.7B, Lincoln Electric $14.2B, WESCO $15.0B, Graco $12.5B, Crane Co $12.6B, Watts Water $12.3B, Donaldson $10.3B, Flowserve $9.2B, CNH Industrial $13.3B. IEX sits at the larger, higher-quality, higher-multiple end of this diversified-machinery cohort — most directly comparable to Nordson and Graco (similarly high-margin, niche-industrial compounders). Its premium multiple is justified only if its margin and M&A track record persist.
9. Management, capital allocation & guidance
- Capital allocation: balanced and shareholder-friendly. FY25 returned $247.8M in buybacks and $212.6M in dividends (dividend $2.86/sh, ~1.3% yield, ~42% payout), while spending ~$76M on bolt-on M&A and only ~$64M on capex. The model is: convert ~18% of sales to FCF, fund the dividend and steady buybacks, and reinvest in accretive niche acquisitions. Net-debt/EBITDA of 1.4× leaves ample dry powder for larger deals.
- Insider activity: CEO Eric Ashleman exercised options and sold ~15,385 shares around $215 in May 2026 (a Rule-10b5-1-style exercise-and-sell), while directors received routine equity awards. Normal diversification and comp — no alarming discretionary selling cluster in the sampled window.
- Management's own guidance (half-weighted — their own book): In the 2026-04-29 Q1'26 earnings release (SEC 8-K, Item 2.02), management raised full-year 2026 guidance: full-year organic sales growth of 3–4% (up from 1–2% prior) and adjusted diluted EPS of $8.35–$8.55 (up from $8.15–$8.35). For Q2'26 they guided organic sales +3–4% and adjusted EPS $2.07–$2.12. CEO Ashleman cited "continued momentum in our growth platforms within HST" and AI-driven demand for data-center power and semiconductors. This is management's self-interested framing and is half-weighted, but the raise is a real, positive datapoint and the record $988M order book supports it.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS ~$2.11, revenue ~$905M). Watch: organic growth vs the 3–4% guide, HST momentum (AI/semis/defense), and whether gross margin stabilizes after the −40bps mix pressure in Q1.
- Order trends: Q1'26 orders were a record $988M (+13%) — a leading indicator; sustained order strength would support the bull case.
- M&A: a larger, value-accretive acquisition would be the clearest path to re-rating (and the biggest execution/overpay risk).
- Industrial cycle: PMI, semiconductor capex, municipal water and life-sciences instrument demand — IEX tracks these.
- Margin trajectory: 80/20 productivity vs price-cost and mix — the key to hitting the raised EPS guide.
Thesis tripwires (what would change the call): two consecutive quarters of negative organic growth; a debt-funded acquisition that pushes net-debt/EBITDA above ~3× without clear accretion; sustained gross-margin erosion; or a re-rating to <20× forward that would flip this from Watch to Buy.
11. Key risks
- Valuation / de-rating (primary): ~26× forward adjusted EPS for ~3–4% organic growth leaves little margin for error; any cyclical or execution wobble invites multiple compression.
- Cyclicality: FMT and FSDP are exposed to industrial, chemical, energy and project-timing cycles; a downturn pressures the ~two-thirds of revenue outside HST's growth platforms.
- M&A dependence: the growth algorithm relies on continually buying niche companies at attractive prices; a dry pipeline or an overpriced deal impairs returns. 67% of assets are goodwill/intangibles — impairment risk if deals disappoint.
- Life-sciences / instrument softness: HST's life-sciences sub-segment saw lower volumes in Q1'26; a prolonged instrument-market slump would blunt the best growth engine.
- No expert corroboration: the Synthos KB has zero coverage, so there is no independent high-conviction thesis (bull or bear) to cross-check the quant call against.
12. Verdict, position sizing & monitoring
Watch. IDEX is a genuinely high-quality niche-industrial compounder — 44% gross margin, ~18% FCF margin, ~9% ROIC, low leverage, a proven 80/20 + bolt-on M&A engine, and a raised FY26 guide backed by a record order book. But at ~26× forward adjusted earnings for ~3–4% organic growth, the market already pays for that quality, our base-case fair value (~$232) sits below the Street's $244.71 consensus, and the sell-side's own rating is a Hold. With no expert-panel conviction in the KB to lean on, there is no case for chasing it at the highs.
- Sizing: if owned, a ~1–2% quality-industrial sleeve position, and preferably initiated on a pullback (toward the 50-DMA ~$215 or into the low-$200s) rather than near the 52-week high. Not a core conviction holding for Synthos today.
- Monitoring: re-underwrite on the tripwires in §10; formal re-score each earnings print. A de-rating to <20× forward, or a clear organic-growth re-acceleration, would move this toward Buy — Tactical.
- Single biggest risk: paying a premium multiple for a cyclical, low-single-digit-organic grower — de-rating if the cycle or the M&A engine stalls.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $223.82.
Provenance & disclosures
- Traceability: 0 KB claims (breadth 0, net conviction 0). This is a fundamentals/quant-only note — no
claim_ids are cited because none exist for IEX. Fabricated conviction is structurally impossible (claim-ID reconciliation) and none is asserted here. - Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-04-29 SEC 8-K earnings release. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Adjusted vs GAAP: management and the analyst-estimate series report on an adjusted EPS basis (FY25 adj ~$7.89 vs GAAP $6.41); forward multiples in this note use adjusted EPS and are labeled.
- Management caveat: management's raised FY26 guidance is their own self-interested book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").